23 results about "Maternal blood" patented technology

The invention relates to a method and kits for isolating and / or purifying nucleic acids, in particular, short-chain nucleic acids, from a nucleic acid containing starting material, characterised by the following method steps: (a) bonding the nucleic acids to a nucleic acid bonding support material, wherein the starting material is brought into contact with the nucleic acid bonding support material in the presence of at least one chaotropic compound and preferably isopropanol, wherein the isopropanol is present in a concentration of ≥15% (v / v) and ≤35% (v / v), (b) optional elution of the bonded nucleic acids from the nucleic acid bonding support material. Said method is particularly suitable for the purification of foetal DNA from maternal blood.

The present disclosure discloses a method for isolating osteoprogenitors like mesenchymal stem cells (MSCs) from clotted bone marrow and culturing with a platelet lysate obtained from a combination of discarded umbilical cord blood and maternal blood platelet-rich plasma (instead of non-human animal origin serum) and differentiating those MSCs into osteoblasts under sterile conditions for further therapeutic applications. Particularly, the present disclosure relates to a method for expansion of osteoblasts to make cell therapy products with a fixed cell dose, which are characterized and later cryopreserved for future use through its cell culture process. Further, the present disclosure relates to identifying specific gene expression from MSCs to osteoblast formation, an in-vitro differentiation process that replicates the in-vivo bone remodelling system.

A method of fetal genotyping, comprises receiving maternal genomic DNA (gDNA) data, maternal cell-free DNA (cfDNA) data, and paternal gDNA data of a pair parenting to a fetus. The data are analyzed to identify a first set of sites at which the parents are homozygous for different alleles, and a second set at which at least one of the parents has a mutation. For each site of the first set, a probability that a respective portion of the maternal cfDNA data is derived from the fetus is determined. Each site of the second set is classified according to the determined probabilities as being either fetal or maternal to genotype the fetus.

The present invention relates to storing and testing for abnormalities in cell free DNA (cfDNA) from blood, such as in maternal blood or blood for cancer screening.

The invention belongs to the technical field of obstetrics and gynecology disease prediction, and particularly relates to a premature fetal membrane premature rupture prediction marker based on maternal circulation exosome microRNA and an application kit. According to the invention, placentas, fetal membranes and plasma exosomes of pregnant women with full-term birth and premature birth premature rupture of fetal membranes are collected for sequencing, the fetal membrane-derived exosome hsa-miR-145-3p which can be detected in the plasma exosomes is screened out in combination with a verification set, and the cell source and the premature birth promoting effect of the fetal membrane-derived exosome hsa-miR-145-3p are respectively clarified at a cell level and an animal level; and finally, by detecting the level of the plasma exosome hsa-miR-145-3p of the pregnant 12 (+ 1)-17 (+ 6) perimaternal body, the efficiency (AUC = 0.833) of the exosome in predicting the occurrence of premature rupture of fetal membranes in premature delivery is illustrated. According to the method, the high-risk crowd of the pPROM can be predicted through a noninvasive method in the early and middle stages of pregnancy, and the method has guiding significance for subsequent prevention and intervention of the high-risk crowd.

The application discloses a labor fetal distress intelligent prediction method and system based on multi-modal data, relates to the technical field of intelligent medical treatment, and aims at the problem that existing single fetal heart monitoring is prone to false positive hypoxia false alarms due to the fact that painless delivery anesthesia induces transient hypotension of puerpera, the application synchronously acquires continuous fetal heart rate, uterine contraction, maternal noninvasive blood pressure and anesthesia pump injection drug data; multi-modal data is input into an artificial intelligence fusion model, anesthetic pharmacokinetic attenuation function is introduced as prior weight, cross attention network is used to extract the space-time implicit correlation features between hemodynamics and fetal heart changes; and then, cause contribution is calculated and dynamic threshold judgment is combined with maternal blood oxygen. The application effectively distinguishes drug compensation reaction from real pathological hypoxia, significantly reduces the false positive alarm rate, and avoids unnecessary emergency cesarean section intervention.

The application provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosing or assisting in diagnosing fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. The application uses miRNA microarray analysis to analyze the expression characteristics of serum exosome microRNAs affected by CHD compared with matched healthy controls. In the early and late pregnancy of TOF fetus, miR-1909-3p is significantly overexpressed in the maternal circulation, indicating that miR-1909-3p is a potential biomarker for fetal congenital heart disease. Through ROC curve analysis of the verification set, it is found that the area under the curve is 0.953, P<0.001, the sensitivity is 95%, and the specificity is 95%, indicating that miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening.

Disclosed is a method for assessing the age of a tissue, in particular the placenta, using circular RNAs. Further disclosed are methods for diagnosing or predicting the risk of a pregnancy complication, such as stillbirth, by quantifying circular RNAs in the placenta or a maternal blood sample.

The invention discloses a nutritional supplement for pregnant pets and a preparation method of the nutritional supplement. According to the preparation method, after chickpeas are hydrolyzed by protease, GAD enzyme and calcium chloride are added, glutamic acid is induced to be converted into GABA through calcium ions, and meanwhile free amino acid reacts with the calcium ions to generate amino acid chelated calcium; the egg yolk powder and the lactoferrin are utilized to construct a double-emulsion system, so that the GABA is protected from being damaged in advance, the amino acid chelated calcium is slowly released, and the absorption antagonism of mineral substances such as calcium, iron and zinc is reduced. The chicken breast, the chicken liver, the traditional Chinese medicines and other raw materials are chopped, mixed and sterilized to obtain a finished product. The nutritional powder is rich in GABA, soybean isoflavone, Omega-3 fatty acid, vitamin B6, lactoferrin, folic acid and various minerals, can directly or indirectly support progestational hormone secretion and relieve anxiety during pregnancy, meets the requirements of maternal blood replenishing and immunity improving and fetal development nutrition supply, and is suitable for nutrition supplement of pets during pregnancy.

The invention belongs to the technical field of medical instruments, and particularly relates to an amniotic fluid sampler for gynaecology and obstetrics, which comprises a puncture frame, an adsorber, a puncture outfit and a controller. The B-ultrasonic probe and the puncture needle are flexibly adjusted and fixed through the installer, and accurate positioning is ensured; the adsorber stably adsorbs the device to the abdomen of a patient through a negative pressure channel and a rubber air cushion, and displacement during operation is prevented; the puncture outfit adopts a specially designed puncture needle and comprises an outer sleeve and a rotatable sampling needle core, so that maternal blood or tissues are prevented from being carried, and the risk of sample pollution is reduced; the controller controls the driving motor through a needle feeding button and a needle withdrawing button, the puncturing depth and speed are automatically adjusted by combining a worm gear, a worm and a lead screw mechanism, and manual operation errors are reduced. According to the whole device, automatic control, stable fixing and clean sampling of amniotic fluid sampling are achieved through the structure, and the detection accuracy and operation convenience are improved.

A method for evaluating fetal DNA concentration (cffDNA) in maternal blood during pregnancy through polymorphic locus linkage block, comprising: obtaining low-depth WGS sequencing data of the sample; obtaining a mapping relationship between the locus and the linkage polymorphism; and calculating the concentration according to the low-depth WGS sequencing data and the mapping relationship between the locus and the linkage polymorphism and taking a plurality of loci constituting the linkage polymorphism as a unit. Wherein, the mapping relationship between the locus and the linkage polymorphism can be obtained by processing public genome WGS data, processing public linkage polymorphism block data or processing a large amount of high-depth WGS measured data. The present application is based on low-depth WGS data, and the heterozygosity of the linkage SNP block can be used to calculate the cffDNA concentration in the maternal blood during pregnancy, which is not affected by the fetal gender in the actual application of NIPT, does not require the father's sample and does not require additional experiments, has high stability, high performance and low cost.

The present invention discloses a maternal blood PBMC / placenta FSTL3 as a warning marker for fetal testicular dysplasia and its application. The present invention proves at the transcriptional level that the epigenetic modification and expression of FSTL3 have the same changes and are significantly correlated in maternal blood PBMC, placenta and offspring fetal testes after prenatal dexamethasone exposure, and the epigenetic modification and expression of FSTL3 can continue to the testes with blood-testis barrier function damage after birth. Therefore, the risk of disease and disease state of offspring testicular dysplasia can be judged by identifying the changes in epigenetic modification and expression of FSTL3 in maternal blood PBMC / placenta. The present invention is reliable and simple, provides a research basis for the early warning technology of testicular dysplasia, and also provides a possibility for the early and effective prevention and treatment of the occurrence of testicular dysplasia.

A non-invasive method for genotyping a fetus is disclosed, the method comprising analyzing sequencing data of maternal free DNA (cfDNA) and genomic DNA (gDNA) of parents (maternal and optionally parent) from a pair of parents rearing the fetus. Accurate genotype prediction is obtained using a variation detection method and evaluation of cfDNA data collected at several points in time.

Disclosed herein are a method, a computer software product, and system embodiments for genotyping a fetus, particularly for identifying short tandem repeat (STR) variants, based on the analysis of cell-free DNA (cfDNA) in a sample of maternal blood plasma. An embodiment comprises: receiving reads of sequencing data of (i) maternal plasma cfDNA, and (ii) maternal and optionally paternal genomic DNA (gDNA) from a pair parenting the fetus; identifying potential genomic sites at which the fetus may have a STR variant; for each of the potential genomic sites, determining a probability that the fetus has the STR variant; deducing maternal and optionally paternal STR alleles; processing cfDNA reads in the region of the gene potentially comprising the STR to identify read categories; calculating the expected ratio between the read categories; and determining the most probable allele inherited by the fetus.

The present invention belongs to the field of biomedicine and relates to the use of leptin in the preparation of a drug for the prevention and / or treatment of preeclampsia. In vitro experiments demonstrate that leptin can promote trophoblast cell syncytialization. Further in vivo experiments confirm that leptin can lower maternal blood pressure and increase placental weight in a rat model of preeclampsia, suggesting broad application prospects in the drug treatment of preeclampsia.

This genetic analysis method comprises: isolating fixed maternal blood cells one by one; de-crosslinking DNA from protein in a proteinase-containing buffer for each of the isolated blood cells; extracting the de-crosslinked DNA; subjecting the extracted DNA to whole genome amplification; and amplifying a target sequence by using a plurality of specific markers from the amplified whole genome amplification product.

The present invention relates to the technical field of lipidomics and human health, and specifically relates to the screening and application of maternal blood lipid biomarkers during pregnancy for fetal growth restriction. The lipid biomarkers are selected from one or any combination of DG 14:0 / 18:2, DG 16:0 / 20:4, TG 14:0 / 16:0 / 18:1, TG 14:0 / 16:0 / 18:2, TG 16:0 / 16:0 / 18:0, and TG 16:0 / 16:0 / 18:1. The lipid biomarkers of the present invention can accurately diagnose the onset of fetal growth restriction and provide a specific and non-invasive diagnostic method for fetal growth restriction.

The present invention relates to the field of biotechnology, specifically to the use of PIK3C3 as a target in monitoring fetal intrauterine development, and specifically to the application of PIK3C3 in monitoring fetal intrauterine developmental abnormalities. The present invention mines and integratively analyzes the sequencing data of maternal blood samples with intrauterine developmental abnormalities, and verifies the high expression of PIK3C3 in samples of fetal intrauterine developmental abnormalities through qPCR experiments designed with specific primers, which makes PIK3C3 applicable to rapid and cost-effective monitoring of fetal intrauterine development.

The present disclosure provides a non-invasive method for early diagnosis of a placental pathology comprising an abnormal formation or arrangement of a placenta in a uterus of a mammalian female subject during pregnancy. Early diagnosis can lead to an improved maternal outcome. The method comprises selectively purifying from plasma of maternal blood a population of small extracellular vesicles (small-EVs) expressing a placenta-specific surface biomarker. The extracellular vesicles comprise micro-RNA cargo. A cargo profile for the small EVs is determined by extracting RNA from the purified population of small EVs. Expression of small non-coding RNAs comprising one or more micro RNAs (miRNAs) encapsulated by the purified population of exosomes is then identified and quantified. The miRNA profile of the placenta specific EVs is then compared to the miRNA profile of a healthy control of the same approximate gestational age.

The invention discloses an application of 3-IAA (3-indoleacetic acid) in preparation of a medicine for improving fetal adult osteoporosis. A fetal adult osteoporosis model is constructed according to the fact that the pregnancy dexamethasone exposure can cause the delayed development of offspring bone and the occurrence of adult osteoporosis, and it is found that the concentration of indole-3-acetic acid (3-IAA) in maternal blood and fetal blood exposed to dexamethasone in the pregnancy is reduced. Based on a rat model of adult offspring osteoporosis caused by pregnancy dexamethasone exposure, 20 mg / kg of 3-IAA is intragastrically fed to GD18-19. D, and the reduction of peak bone mass of female adult offspring caused by pregnancy dexamethasone exposure can be effectively reversed by 3-IAA. Therefore, the 3-IAA provides a new way for preventing and treating the fetal adult osteoporosis.

The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital analysis is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.

The present disclosure provides a non-invasive method for early diagnosis of a placental pathology comprising an abnormal formation or arrangement of a placenta in a uterus of a mammalian female subject during pregnancy. Early diagnosis can lead to an improved maternal outcome. The method comprises selectively purifying from plasma of maternal blood a population of small extracellular vesicles (small-EVs) expressing a placenta-specific surface biomarker. The extracellular vesicles comprise micro-RNA cargo. A cargo profile for the small EVs is determined by extracting RNA from the purified population of small EVs. Expression of small non-coding RNAs comprising one or more micro RNAs (miRNAs) encapsulated by the purified population of exosomes is then identified and quantified. The miRNA profile of the placenta specific EVs is then compared to the miRNA profile of a healthy control of the same approximate gestational age.

The present disclosure provides a non-invasive method for early diagnosis of a placental pathology comprising an abnormal formation or arrangement of a placenta in a uterus of a mammalian female subject during pregnancy. Early diagnosis can lead to an improved maternal outcome. The method comprises selectively purifying from plasma of maternal blood a population of small extracellular vesicles (small-EVs) expressing a placenta-specific surface biomarker. The extracellular vesicles comprise micro-RNA cargo. A cargo profile for the small EVs is determined by extracting RNA from the purified population of small EVs. Expression of small non-coding RNAs comprising one or more micro RNAs (miRNAs) encapsulated by the purified population of exosomes is then identified and quantified. The miRNA profile of the placenta specific EVs is then compared to the miRNA profile of a healthy control of the same approximate gestational age.